Does Baseline Diuretics Use Affect Prognosis in Patients With COVID-19?
ace inhibitors and angiotensin receptor blockers
anticoagulation
coronavirus disease 2019 (covid-19)
diuretics
mortality
severity
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
10
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
The rapid emergence of coronavirus disease 2019 (COVID-19) has become the biggest healthcare crisis of the last century, resulting in thousands of deaths worldwide. There have been studies that evaluated the role of angiotensin-converting enzyme (ACE) inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in treating patients with COVID-19. However, the prior use of diuretics and their effect on mortality in this setting remains unknown. The aim of the study was to evaluate the effect of diuretics in patients admitted with COVID-19. The current study was conducted between March 15, 2020, and April 30, 2020, during the COVID-19 pandemic in three different hospitals in Northern New Jersey, USA. The primary outcome was survival or in-hospital mortality from COVID-19 from the day of admission. The secondary outcome was severe or non-severe illness from COVID-19. This retrospective study included a total of 313 patients with a median age of 61.3 ± 14.6 years. There was a total of 68 patients taking diuretics at home and 245 patients who were not taking diuretics. There was a total of 39 (57.35%) deaths in patients taking diuretics as compared to 93 (37.96%) deaths in patients not taking diuretics (p-value 0.0042). Also, 54 (79.41%) patients who took diuretics had severe COVID-19 illness as compared to 116 (47.35%) who did not take diuretics (p-value <.0001). However, after adjusting for the confounding factors, there was no difference in mortality or severity of illness in COVID-19 patients taking diuretics at the time of admission. In conclusion, there was no effect of the baseline use of diuretics in the prognosis of COVID-19.
Identifiants
pubmed: 34277195
doi: 10.7759/cureus.15573
pmc: PMC8272599
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15573Informations de copyright
Copyright © 2021, Guragai et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2002 Nov 27;288(20):2547-53
pubmed: 12444861
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
J Korean Med Sci. 2020 Jun 15;35(23):e209
pubmed: 32537954
N Engl J Med. 2020 Jun 25;382(26):2582
pubmed: 32501665
Crit Care Med. 2015 Feb;43(2):288-95
pubmed: 25599463
Heart Lung. 2020 Nov - Dec;49(6):894-895
pubmed: 32693957
Ann Am Thorac Soc. 2020 Apr 24;:
pubmed: 32330073
Anaesthesia. 2020 Jan;75 Suppl 1:e134-e142
pubmed: 31903562
Hypertension. 2020 Jul;76(1):51-58
pubmed: 32348166
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
N Engl J Med. 2006 Jun 15;354(24):2564-75
pubmed: 16714767
Echocardiography. 2020 Sep;37(9):1362-1365
pubmed: 32789869
Proc (Bayl Univ Med Cent). 2020 Apr 16;0(0):1-6
pubmed: 32336959